Cas:956102-64-0 (2S)-2-Amino-2,3-dimethyl-1-butanol manufacturer & supplier

Chemical Name:(2S)-2-Amino-2,3-dimethyl-1-butanol

CAS.NO:956102-64-0

Synonyms:(2S)-2-Amino-2,3-dimethyl-1-butanol

Molecular Formula:C₆H₁₅NO

Molecular Weight:117.18900

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:46.25000

Exact Mass:117.11500

LogP:1.05240

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (2S)-2-Amino-2,3-dimethyl-1-butanol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2S)-2-Amino-2,3-dimethyl-1-butanol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(2S)-2-Amino-2,3-dimethyl-1-butanol Use and application,(2S)-2-Amino-2,3-dimethyl-1-butanol technical grade,usp/ep/jp grade.

Related News: The complete chemical and pharmaceutical industry chain consists of basic chemical raw materials, pharmaceutical intermediates, chemical raw materials and chemical preparations. (2S)-2-Amino-2,3-dimethyl-1-butanol manufacturer The complete chemical and pharmaceutical industry chain consists of basic chemical raw materials, pharmaceutical intermediates, chemical raw materials and chemical preparations. (2S)-2-Amino-2,3-dimethyl-1-butanol supplier GlaxoSmithKline��s HIV drugs division ViiV Healthcare said on Saturday that the U.S. Food and Drug Administration declined to approve its long acting HIV injection. (2S)-2-Amino-2,3-dimethyl-1-butanol vendor The risk-based score generated by the tool helps sponsors gain advance understanding of the appropriate level of clinical supply management oversight needed to help get their project started on time and maintain momentum as the study progresses. (2S)-2-Amino-2,3-dimethyl-1-butanol factory China has granted conditional approval to its first self-developed treatment for Alzheimer��s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug.